Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Benjamin Miron MD

Benjamin Miron MD

Instructor, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Dr. Benjamin Miron is an Instructor in Hematology/Oncology at Fox Chase Cancer Center, a practicing oncologist and researcher specializing in genitourinary cancers.

Dr. Miron received his undergraduate degree from New York University (NYU) and his MD degree from NYU School of Medicine with honors in recognition of his research in immunology. He completed his residency at Temple University Hospital and is board certified to practice Internal Medicine.

Dr. Miron has been involved in oncology research since completion of his undergraduate degree first, working in the clinical trials office at Memorial Sloan-Kettering Cancer Center and subsequently in biotechnology companies after graduating from medical school. He has completed clinical fellowship training as part of the ABIM research pathway in Hematology/Oncology at Fox Chase Cancer Center, as well as graduate training in bioinformatics at Temple University.

His research focuses on developing clinical trials focusing on novel molecular diagnostic tests, predictive and prognostic biomarkers and translational research in genomics. The fundamental goal of his research is to improve treatment paradigms for patients with genitourinary malignancies by individualizing therapy for each patient to maximize benefit and minimize toxicity.


Consulting/Advisory: Astellas, Seagen, OncLive, TargetedOncology